Ann: Half Yearly Report and Accounts, page-8

Hi Raysea,

I think it's a big ask for the company to expect any sales from India/Medachievers to date. Primarily because the company has not finished its studies/trials (as per last announcements on the subject), and has not displayed capabilities of manufacturing at scale, or servicing the market post launch. New CEO Marjan M. has expressed the importance of sales being clinically driven rather than via consumer marketing. This should be the same focus in India also. ie if the company is not ready to sell in Australia it's not ready to sell in India.

Having said all this, clearly the company is in a much stronger position in regards to internal capabilities vs 2019. So when the company can display the evidence/confidence from trial/study data, and when it can display it's ready to manufacture at scale (profitably), then Respiri should be able to capitalise on Medachievers work in India creating awareness of the product/technology.